3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
34
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Ovarian Neoplasms
3
Neoplasms
3
Brain Neoplasms
3
Skin Neoplasms
2
Neoplasms by Site
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Noonan Syndrome
1
Neoplasms, Squamous Cell
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Lung Neoplasms
1
Lung Diseases
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Interventions
trametinib
2
dabrafenib
2
binimetinib
2
Trastuzumab
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Cisplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
sapanisertib
1
romidepsin
1
ripretinib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
erdafitinib
1
entrectinib
1
entinostat
1
efineptakin alfa
1
durvalumab
1
defactinib
1
copanlisib
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
cobimetinib
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled